Paris-based Klineo has raised €2mn for its AI platform that facilitates access to cancer clinical trials. Klineo’s platform connects doctors and patients directly with relevant clinical trials. It provides trial search, contact with medical centres, as well as real-time updates and notifications when a new clinical trial matches the patient’s criteria. The startup’s solution currently covers trials on skin cancer, breast cancer, and lymphoma. Klineo was founded in 2021 by oncologist Dr Arnaud Bayle and two engineers, Thomas Peyresblanques and Nicolas Drizard. The startup aims to accelerate the inclusion of patients in clinical trials, which play a key role in…This story continues at The Next Web

View Entire Post